{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:19:44Z","timestamp":1791584384061,"version":"4.3.4"},"reference-count":50,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2022,7,12]]},"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Myeloid sarcoma (MS) is a rare tumour comprising myeloid blasts occurring at an anatomical site other than the bone marrow. We sought to investigate both paediatric and adult patients with MS diagnosed at our institution and determine possible correlations among their clinicopathological, phenotypic, molecular and prognostic features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study retrospectively evaluated the data of 45 patients diagnosed with MS at Ege University Faculty of Medicine Hospital, Turkey, over a 17-year period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The male-to-female ratio was 1.5:1, and the median age was 39.12 years. The most commonly involved sites were the skin, lymph nodes, soft tissues and bone. Immunohistochemically, CD68-KP1 was the most commonly expressed marker, followed by CD33, myeloperoxidase, CD117, lysozyme, CD68-PGM1 and CD34. Of the patients, 26 (57.7%) presented with de novo MS, 7 (15.5%) had simultaneous acute myeloid leukaemia and 12 (26.8%) had a previous history of haematological disorders. Kaplan-Meier survival analysis revealed that the 2-year and 5-year overall survival (OS) rates were 46.4% and 39.8%, respectively; the median OS duration was 11 months. Increasing age had a negative prognostic relationship with survival (p\u200a=\u200a0.04). Chromosomal abnormalities were detected in approximately 6\/10 (60%) of paediatric patients and 6\/9 (66.7%) of adult patients. t(8;21)(q22;q22) translocation was identified in 20% of paediatric patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MS diagnosis is usually challenging; an expanded immunohistochemical panel should be used for an accurate diagnosis. Although MS generally has a poor prognosis, increasing age appears to be associated with a worse outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jcp-2021-208000","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T13:25:20Z","timestamp":1659619520000},"page":"244-251","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Clinicopathological characteristics, genetics and prognosis of patients with myeloid sarcoma: a single-center study"],"prefix":"10.1136","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-8856","authenticated-orcid":false,"given":"Derya","family":"Demir","sequence":"first","affiliation":[{"name":"Pathology, Ege University Faculty of Medicine, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mine","family":"Hekimgil","sequence":"additional","affiliation":[{"name":"Pathology, Ege University Faculty of Medicine, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emin","family":"Karaca","sequence":"additional","affiliation":[{"name":"Medical Genetics, Ege University Faculty of Medicine, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4408-3544","authenticated-orcid":false,"given":"Yusuf","family":"Ulusoy","sequence":"additional","affiliation":[{"name":"Internal Medicine, Division of Hematology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamiyet Hekimci","family":"\u00d6zdemir","sequence":"additional","affiliation":[{"name":"Pediatric Hematology-Oncology, Ege University Faculty of Medicine, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcray","family":"Saydam","sequence":"additional","affiliation":[{"name":"Internal Medicine, Division of Hematology, Ege University Faculty of Medicine, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Durmaz","sequence":"additional","affiliation":[{"name":"Medical Genetics, Ege University Faculty of Medicine, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haluk","family":"Ak\u0131n","sequence":"additional","affiliation":[{"name":"Medical Genetics, Ege University Faculty of Medicine, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazan","family":"\u00c7eting\u00fcl","sequence":"additional","affiliation":[{"name":"Pediatric Hematology-Oncology, Ege University Faculty of Medicine, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Tombulo\u011flu","sequence":"additional","affiliation":[{"name":"Internal Medicine, Division of Hematology, Ege University Faculty of Medicine, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazan","family":"\u00d6zsan","sequence":"additional","affiliation":[{"name":"Pathology, Ege University Faculty of Medicine, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"2025112108341527000_76.4.244.1","unstructured":"Swerdlow SH , Campo E , Harris NL , et al . WHO classification of tumours of haematopoietic and lymphoid tissues. In: 4th ed. International agency for research on Cancer, 2017."},{"key":"2025112108341527000_76.4.244.2","first-page":"97","article-title":"Case of chloroma","volume":"8","author":"King","year":"1853","journal-title":"Mon J Med Sci"},{"key":"2025112108341527000_76.4.244.3","unstructured":"Burns A . Observation of surgical anatomy of the head and neck, 1811: 364\u20136."},{"key":"2025112108341527000_76.4.244.4","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP1ZA7HYZKAZHS"},{"key":"2025112108341527000_76.4.244.5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.1999.00651.x"},{"key":"2025112108341527000_76.4.244.6","unstructured":"Jaffe ES , Harris NL , Stein HVJ . Pathology and genetics: tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001: 104\u20135."},{"key":"2025112108341527000_76.4.244.7","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.2147\/OTT.S134584","article-title":"Clinical targeting recombinant immunotoxins for cancer therapy","volume":"10","author":"Li","year":"2017","journal-title":"Onco Targets Ther"},{"key":"2025112108341527000_76.4.244.8","doi-asserted-by":"crossref","first-page":"823","DOI":"10.5858\/2002-126-0823-CQIITB","article-title":"CD34\/QBEND10 immunostaining in the bone marrow trephine biopsy: a study of CD34-positive mononuclear cells and megakaryocytes","volume":"126","author":"Torlakovic","year":"2002","journal-title":"Arch Pathol Lab Med"},{"key":"2025112108341527000_76.4.244.9","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.037507"},{"key":"2025112108341527000_76.4.244.10","first-page":"33","article-title":"Immunohistochemical diagnosis of gastrointestinal stromal tumors - an analysis of 80 cases from 2004 to 2010","volume":"22","author":"Ki\u015bluk","year":"2013","journal-title":"Adv Clin Exp Med"},{"key":"2025112108341527000_76.4.244.11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404491"},{"key":"2025112108341527000_76.4.244.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"2025112108341527000_76.4.244.13","unstructured":"Mitelman F . An international system for human cytogenetic nomenclature. Basel: S. Karger Publishers, 1995."},{"key":"2025112108341527000_76.4.244.14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404699"},{"key":"2025112108341527000_76.4.244.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.01.022"},{"key":"2025112108341527000_76.4.244.16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4274\/tjh.2013.0087","article-title":"Myeloid sarcomas: a clinicopathologic study of 20 cases","volume":"32","author":"Kaygusuz","year":"2015","journal-title":"Turk J Haematol"},{"key":"2025112108341527000_76.4.244.17","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600967196"},{"key":"2025112108341527000_76.4.244.18","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/ejh.13056","article-title":"Clinicopathological characteristics of de novo and secondary myeloid sarcoma: a monocentric retrospective study","volume":"100","author":"Claerhout","year":"2018","journal-title":"Eur J Haematol"},{"key":"2025112108341527000_76.4.244.19","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3892\/mco.2016.836","article-title":"Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to Ras and BRAF mutation subgroups: a meta-analysis","volume":"4","author":"Lin","year":"2016","journal-title":"Mol Clin Oncol"},{"key":"2025112108341527000_76.4.244.20","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810915)48:6<1426::AID-CNCR2820480626>3.0.CO;2-G"},{"key":"2025112108341527000_76.4.244.21","first-page":"62","article-title":"Extramedullary myeloid cell tumors arising in the setting of chronic myelomonocytic leukemia. A report of two cases","volume":"120","author":"Elenitoba-Johnson","year":"1996","journal-title":"Arch Pathol Lab Med"},{"key":"2025112108341527000_76.4.244.22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/PAI.0000000000000783","article-title":"Myeloid sarcoma of the testis in children: clinicopathologic and immunohistochemical characteristics with KMT2A (MLL) gene rearragement correlation","volume":"28","author":"El Jamal","year":"2020","journal-title":"App Immunohistochem Mol Morphol"},{"key":"2025112108341527000_76.4.244.23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.prp.2016.06.014","article-title":"Clinicopathological features of myeloid sarcoma: report of 39 cases and literature review","volume":"212","author":"Wang","year":"2016","journal-title":"Pathol Res Pract"},{"key":"2025112108341527000_76.4.244.24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"2025112108341527000_76.4.244.25","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800768"},{"key":"2025112108341527000_76.4.244.26","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1182\/blood.V85.8.2005.bloodjournal8582005","article-title":"Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules","volume":"85","author":"Freeman","year":"1995","journal-title":"Blood"},{"key":"2025112108341527000_76.4.244.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb03021.x"},{"key":"2025112108341527000_76.4.244.28","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9674"},{"key":"2025112108341527000_76.4.244.29","doi-asserted-by":"publisher","DOI":"10.1309\/E36008Y2H08Q1AYY"},{"key":"2025112108341527000_76.4.244.30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/10428194.2017.1339879","article-title":"Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing","volume":"59","author":"Kashofer","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"2025112108341527000_76.4.244.31","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.213"},{"key":"2025112108341527000_76.4.244.32","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1182\/blood.V96.12.3887","article-title":"A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by Mll-Ell","volume":"96","author":"DiMartino","year":"2000","journal-title":"Blood"},{"key":"2025112108341527000_76.4.244.33","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.79","article-title":"Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set","volume":"7","author":"Goyal","year":"2017","journal-title":"Blood Cancer J"},{"key":"2025112108341527000_76.4.244.34","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/PAS.0000000000000727","article-title":"Clinicopathological, cytogenetic, and prognostic analysis of 131 myeloid sarcoma patients","volume":"40","author":"Kawamoto","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"2025112108341527000_76.4.244.35","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3109\/10428194.2014.963080","article-title":"Presentation and outcomes among patients with isolated myeloid sarcoma: a surveillance, epidemiology, and end results database analysis","volume":"56","author":"Movassaghian","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2025112108341527000_76.4.244.36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/his.13864","article-title":"Clinicopathological and molecular characteristics of extramedullary acute myeloid leukaemia","volume":"75","author":"Ullman","year":"2019","journal-title":"Histopathology"},{"key":"2025112108341527000_76.4.244.37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/10245332.2017.1333275","article-title":"Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years","volume":"23","author":"Kaur","year":"2018","journal-title":"Hematology"},{"key":"2025112108341527000_76.4.244.38","doi-asserted-by":"crossref","first-page":"314","DOI":"10.5414\/NP300949","article-title":"Central nervous system involvement by myeloid sarcoma: a report of 12 cases and review of the literature","volume":"35","author":"Olar","year":"2016","journal-title":"Clin Neuropathol"},{"key":"2025112108341527000_76.4.244.39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/neurosurgery\/46.1.78","article-title":"Granulocytic sarcoma of the spine","volume":"46","author":"Mostafavi","year":"2000","journal-title":"Neurosurgery"},{"key":"2025112108341527000_76.4.244.40","doi-asserted-by":"crossref","DOI":"10.1186\/1746-1596-2-7","article-title":"Primary histiocytic sarcoma arising in the head and neck with predominant spindle cell component","volume":"2","author":"Alexiev","year":"2007","journal-title":"Diagn Pathol"},{"key":"2025112108341527000_76.4.244.41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00381-002-0553-8","article-title":"Isolated meningeal chloroma (granulocytic sarcoma) in a child with acute lymphoblastic leukemia mimicking a falx meningioma","volume":"18","author":"Ahn","year":"2002","journal-title":"Childs Nerv Syst"},{"key":"2025112108341527000_76.4.244.42","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-006-9163-8"},{"key":"2025112108341527000_76.4.244.43","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1200\/JCO.1995.13.7.1800","article-title":"Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review","volume":"13","author":"Byrd","year":"1995","journal-title":"J Clin Oncol"},{"key":"2025112108341527000_76.4.244.44","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2025112108341527000_76.4.244.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2014.04.001"},{"key":"2025112108341527000_76.4.244.46","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.52"},{"key":"2025112108341527000_76.4.244.47","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70281-5"},{"key":"2025112108341527000_76.4.244.48","article-title":"Cytogenetic, and outcome analysis of 21 adult patients","volume":"2011","author":"Al-khateeb","year":"2011","journal-title":"Leuk Res Treatment"},{"key":"2025112108341527000_76.4.244.49","doi-asserted-by":"crossref","DOI":"10.1186\/1748-717X-8-245","article-title":"Clinicopathologic features and responses to radiotherapy of myeloid sarcoma","volume":"8","author":"Chen","year":"2013","journal-title":"Radiat Oncol"},{"key":"2025112108341527000_76.4.244.50","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/08880018.2019.1683107","article-title":"Pediatric myeloid sarcoma: a single institution clinicopathologic and molecular analysis","volume":"37","author":"Zhou","year":"2020","journal-title":"Pediatr Hematol Oncol"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp-2021-208000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T16:34:28Z","timestamp":1763742868000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp-2021-208000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,3,17]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1136\/jcp-2021-208000"],"URL":"https:\/\/doi.org\/10.1136\/jcp-2021-208000","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]}}}